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OBJECTIVES This study sought to determine the impact of surgical myectomy on long-term survival in
hypertrophic cardiomyopathy (HCM).
BACKGROUND Left ventricular (LV) outflow tract obstruction in HCM increases the likelihood of heart
failure and cardiovascular death. Although surgical myectomy is the primary treatment for
amelioration of outflow obstruction and advanced drug-refractory heart failure symptoms, its
impact on long-term survival remains unresolved.
METHODS Total and HCM-related mortality were compared in three subgroups comprised of 1,337
consecutive HCM patients evaluated from 1983 to 2001: 1) surgical myectomy (n  289); 2)
LV outflow obstruction without operation (n 228); and 3) nonobstructive (n 820). Mean
follow-up duration was 6  6 years.
RESULTS Including two operative deaths (procedural mortality, 0.8%), 1-, 5-, and 10-year overall
survival after myectomy was 98%, 96%, and 83%, respectively, and did not differ from that of the
general U.S. population matched for age and gender (p  0.2) nor from patients with
nonobstructive HCM (p  0.8). Compared to nonoperated obstructive HCM patients,
myectomy patients experienced superior survival free from all-cause mortality (98%, 96%, and 83%
vs. 90%, 79%, and 61%, respectively; p  0.001), HCM-related mortality (99%, 98%, and 95%
vs. 94%, 89%, and 73%, respectively; p 0.001), and sudden cardiac death (100%, 99%, and 99%
vs. 97%, 93%, and 89%, respectively; p 0.003). Multivariate analysis showed myectomy to have
a strong, independent association with survival (hazard ratio 0.43; p  0.001).
CONCLUSIONS Surgical myectomy performed to relieve outflow obstruction and severe symptoms in HCM
was associated with long-term survival equivalent to that of the general population, and
superior to obstructive HCM without operation. In this retrospective study, septal myectomy
seems to reduce mortality risk in severely symptomatic patients with obstructive
HCM. (J Am Coll Cardiol 2005;46:470–6) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.090Cardiology Foundation
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Seft ventricular (LV) outflow tract obstruction is an impor-
ant pathophysiologic component of hypertrophic cardio-
yopathy (HCM) and an independent determinant of
See page 477
rogressive heart failure disability and cardiovascular death
1–7). Indeed, the presence of outflow obstruction has been
prerequisite for major therapeutic interventions to relieve
evere drug-refractory heart failure symptoms (1–3,6).
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005, accepted February 14, 2005.Surgical septal myectomy has been performed effectively
or over 40 years as the primary treatment strategy for such
CM patients of all ages, with substantial long-term
emodynamic and symptomatic benefits attributable to the
peration (8–28). However, a major unresolved issue con-
erns whether surgical myectomy, often performed in rela-
ively young patients, has a beneficial impact on long-term
urvival. A unique aspect of this study is the opportunity to
ompare long-term outcome in a large surgical series with
hat in a cohort of medically managed HCM patients, as
ell as the expected survival in the general population, to
etermine whether surgical relief of LV outflow obstruction
y myectomy has clinical benefit beyond improvement in
he quality of life.
ETHODS
election of patients. The study population of 1,337
onsecutive HCM patients is composed of three retrospec-
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August 2, 2005:470–6 Survival After Myectomy for HCMively identified subgroups evaluated from 1983 to 2001:
89 patients with isolated surgical ventricular septal myec-
omy at Mayo Clinic; 64 other patients with myectomy
uring this period who had additional operative procedures
erformed concomitantly (e.g., valve replacement, coronary
rtery bypass grafting) were excluded. The Mayo Clinic is a
ong-standing tertiary HCM center with patients referred
n a national basis, and has maintained a special expertise in
erforming the septal myectomy operation for over 40 years.
omparison subgroups totaling 1,048 nonoperated HCM
atients were included in this study: 1) 228 patients with left
entricular outflow obstruction 30 mm Hg at rest; these
atients had not been recommended for myectomy largely
ecause of insufficiently advanced symptoms or because of
ngoing medical treatment for severe functional limitation;
nd 2) 820 patients without outflow obstruction who, by
onvention, were not considered candidates for surgery.
hese two comparison groups were assembled from three
ther HCM centers with large cohorts but not with spe-
ialized surgical experience in this disease (Minneapolis
eart Institute Foundation; Azienda Ospedaliera Careggi,
lorence, Italy; and Federico II University of Naples, Italy).
elected clinical data from these 1,048 patients have been
ncluded in a prior report (4).
The most recent vital status was obtained for each of the
,337 study patients by clinic visit or mailed questionnaire.
his study received approval by institutional review board
or its equivalent) at each participating center.
chocardiography. The diagnosis of HCM was based on
he presence of a hypertrophied nondilated LV in the
bsence of other diseases capable of producing the magni-
ude of the hypertrophy evident (29). Echocardiographic
arameters were measured as previously described (4,29).
he LV outflow tract gradient was assessed under resting
basal) conditions, using continuous wave Doppler echocar-
iography (4,29), at the initial evaluation in the participat-
ng institution (or just before myectomy), and also 3.2  3
ears after myectomy.
urgery. Criteria for surgical intervention at the Mayo
linic were LV outflow obstruction 50 mm Hg at rest or
ith provocative maneuvers attributable to systolic anterior
otion of the mitral valve, associated with New York Heart
ssociation (NYHA) functional classes III to IV limitation
or repetitive and disabling effort-related syncope) despite
aximum medical management (6,7,24). The septal myec-
omy operation in the present cohort was predominantly
hat described by Morrow et al. (8,10,11). This procedure,
erformed through an aortotomy, creates a rectangular
Abbreviations and Acronyms
HCM  hypertrophic cardiomyopathy
LV  left ventricle/ventricular
NYHA  New York Heart Associationrough via two parallel longitudinal incisions in the basal septum. Incisions are connected proximally below the aortic
alve and extended distally just beyond the level of mitral-
eptal contact and subaortic obstruction, or in some patients
o the base of the papillary muscles (i.e., extended
yectomy).
tatistical analysis. Data are expressed as mean  SD.
ne-way analysis of variance was used to compare normally
istributed data. Noncontinuous data were analyzed using
hi-square tests. The p values are two-sided; p  0.05 was
onsidered statistically significant.
The survival analysis model used proportional hazards
egression methodology; Kaplan-Meier survival curves were
ompared using log-rank statistics. End points were all-
ause mortality and HCM-related mortality. Deaths within
0 days after myectomy were considered operative deaths
nd are included in both end points. The HCM mortality
ncluded sudden cardiac death (unexpected within 1 h of
itnessed collapse or nocturnal), heart failure death (in
ontext of progressive cardiac decompensation), and stroke-
elated death (30). Appropriate discharges from implantable
efibrillators for ventricular fibrillation or sustained ventric-
lar tachycardia (n  8) were regarded as sudden deaths
30). Survival was censored at cardiac transplantation in 9
atients with end-stage heart failure and at the time of
ercutaneous septal ablation in 20 nonoperated patients
ith LV outflow obstruction.
Follow-up for nonoperated HCM patients began at the
nitial clinical evaluation at the participating institution. For
yectomy patients, follow-up began on the day of operation
4.8  12 months after initial evaluation). Mean follow-up
uration was 6.2  6 years.
To determine whether differences in survival between the
yectomy and the other nonoperated HCM groups could
e explained by disease-related variables other than the
peration, univariate and multivariate Cox proportional
azard regression analyses were performed (Table 1). Sta-
istically significant variables from the univariate analysis
ere entered stepwise into the multivariate regression
odel.
For comparison with myectomy patients, an expected
urvival curve for the general population was generated from
.S. Health Statistics, which incorporate all-cause mortality
31). Each myectomy patient was matched to the U.S. white
opulation by age, gender, and year of study entry.
ESULTS
aseline characteristics. Myectomy and nonoperated ob-
tructive HCM patients were similar with respect to the
nitial LV outflow gradient at rest (67 vs. 68 mm Hg,
espectively; p  0.9) (Table 1). Myectomy patients were
ounger (45 vs. 50 years; p  0.01) and had larger left atrial
47 vs. 45 mm; p  0.001) and LV end-diastolic cavity
imensions (44 vs. 42 mm; p  0.001). Because advanced
ymptoms refractory to pharmacologic therapy represent the
tandard indication for operation, myectomy patients ex-
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Survival After Myectomy for HCM August 2, 2005:470–6ectedly showed more severe functional disability at study
ntry: 89% in NYHA functional classes III to IV compared
ith 15% in the nonoperated obstructive HCM group (p 
.001).
linical benefits of myectomy. The surgical myectomy
roup experienced substantial symptomatic and hemody-
amic improvement after myectomy; 255 (89%) patients
ere in NYHA functional classes III to IV before operation,
hereas only 12 (6%) were in classes III to IV at the most
ecent follow-up. The mean functional class was 2.9  0.7
efore myectomy and 1.5  0.7 at last postmyectomy
ollow-up (p  0.001). The average preoperative outflow
radient at rest was 67  41 mm Hg, and decreased to 3 
mm Hg postoperatively (p  0.001). Nonfatal complica-
ions included ventricular septal defect in two patients
0.8%) and complete heart block requiring permanent pace-
aker in three (1%).
urvival after myectomy. There were 25 deaths after
yectomy, including 2 related to operation (operative mor-
ality, 0.8%); both operative deaths involved patients with
YHA functional class IV heart failure who underwent
mergency myectomy at 64 and 71 years of age. Seven other
eaths were probably or definitely caused by HCM (5
udden deaths and 2 due to heart failure), and 16 were
able 1. Baseline Clinical and Demographic Data in Three Hype
Parameter
All Patients
(n  1,337)
M
(n
ge (yrs) 45.3  20 45
ale gender 779 (58) 1
YHA functional class (at entry)
Mean 1.83  0.9 2.
I 608 (45)
II 380 (28)
III to IV 348 (26) 2
trial fibrillation 259 (19)
AD-documented medications 41 (3)
Beta-blocker 570 (43) 1
Calcium-blocker 466 (35) 1
Disopyramide 56 (4)
Amiodarone 154 (12)
chocardiography
ax LV thickness (mm) 22.5  6 23
A diameter (mm) 42.9  9 47
VEDD (mm) 43.5  7 43
V outflow gradient (at rest) (mm Hg) 29.2  39 67
evere MR 71 (5)
ollow-up
Duration 6.2  6 5
Mode of death
Sudden 47 (4)
Heart failure 33 (2)
Stroke 14 (1)
Non-cardiac 71 (5)
Operative 2 (1)
Obstruction defined as peak instantaneous left ventricular (LV) outflow gradient 
s number of patients with percentage in parentheses. †p  0.01 and ‡p  0.05 for
ANOVA  analysis of variance; CAD  coronary artery disease; LA  left at
egurgitation; NYHA  New York Heart Association.oncardiac deaths. Mean age at death was 64  12 years srange, 22 to 82 years), occurring 6.8  5 years (range, 0.2
o 17 years) after myectomy.
The 1-, 5-, and 10-year overall survival after myectomy
as 98%, 96%, and 83%, respectively, and did not differ
rom the age- and gender-matched general population
98%, 95%, and 88%, respectively; log-rank p  0.2)
Fig. 1).
urvival comparisons in patients with obstructive
CM. Among patients with LV outflow tract obstruction
n  517), overall survival of myectomy patients was
ignificantly better than that of nonoperated obstructive
CM patients (98%, 96%, and 83% vs. 90%, 79%, and 61%
t 1, 5, and 10 years, respectively; log-rank p  0.001) (Fig.
). Baseline parameters with significant univariate associa-
ion to improved survival included myectomy (p  0.001),
ale gender (p  0.01), younger age (p  0.001), lower
YHA functional class (p  0.001), absence of atrial
brillation (p 0.02), and absence of documented coronary
rtery disease (p  0.03). With these variables entered into
he multivariate model, the only independent predictors of
mproved survival were myectomy (hazard ratio [HR] 0.43,
 0.001) and younger age at study entry (HR 0.97 per
ear decrement of age; p  0.001).
Similarly, survival free from HCM-related death was also
hic Cardiomyopathy Patient Subgroups
my
89)
Nonoperated
Obstructive*
(n  228)
Nonobstructive
(n  820)
ANOVA
p Value
19† 50.0  22 44.0  19 0.001
1) 106 (46) 525 (64) 0.001
0.7† 1.74  0.8 1.49  0.6 0.001
)† 98 (43) 488 (60) —
)† 95 (42) 274 (33) —
9)† 34 (15) 58 (7) —
0) 56 (25) 144 (18) 0.05
) 10 (4) 21 (3) 0.33
0) 125 (55) 272 (33) 0.001
0) 92 (40) 258 (31) 0.005
1) 14 (6) 11 (1) 0.001
)† 30 (13) 112 (14) 0.001
7 23.7  7 21.8  6 0.001
8† 44.6  8 41.4  8 0.001
7† 41.5  6 43.9  7 0.001
41 68.0  31 5.1  7 —
) 24 (8) 26 (3) 0.001
4‡ 4.9  5 6.6  6 0.001
) 16 (7) 26 (3) —
1) 10 (4) 21 (3) —
6 (3) 8 (1) —
) 22 (10) 37 (5) —
1) 0 0 —
Hg under resting conditions. Data are expressed as mean  standard deviation or
arison of myectomy versus nonoperated obstructive groups.
VEDD  left ventricular end-diastolic diameter; Max  maximal; MR  mitralrtrop
yecto
 2
.3 
48 (5
89 
22 (7
11 (4
56 (8
59 (2
10 (3
73 (6
16 (4
31 (1
12 (4
.5 
.4 
.9 
.3 
21 (7
.8 
5 (2
2 (
0
16 (5
2 (
30 mm
compuperior in myectomy patients compared with nonoperated
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August 2, 2005:470–6 Survival After Myectomy for HCMbstructive HCM patients (99%, 98%, and 95% vs. 94%,
9%, and 73%, respectively; log-rank p  0.001) (Fig. 3).
ultivariate analysis showed that only myectomy (HR,
.09; p  0.001) and smaller left atrial dimension (HR 0.94
er ml decrement; p  0.003) were independently associ-
ted with HCM-related survival.
Myectomy patients also showed a significantly lower risk
pecifically for sudden cardiac death compared with nonop-
rated obstructive HCM patients (100%, 99%, and 99% vs.
7%, 93%, and 89%, respectively; HR 0.27; log-rank p
.003) (Fig. 4).
urvival comparisons including obstructive and nonob-
tructive HCM patients. Compared with nonobstructive
atients (overall survival 98%, 95%, and 87%, respec-
ively; HCM-related survival 98%, 96%, and 91%, re-
pectively), the myectomy patients showed statistically
ndistinguishable overall survival (p  0.8) (Fig. 2), but
uperior HCM-related survival (p  0.01) (Fig. 3). Multi-
igure 1. Survival free from all-cause mortality after surgical myectomy for
bstructive hypertrophic cardiomyopathy (n  289) compared with the age-
nd gender-matched general U.S. white population. Log-rank, p  0.2.
igure 2. Survival free from all-cause mortality in three hypertrophic
ardiomyopathy patient subgroups: surgical myectomy (n  289), nonop-
rated with obstruction (n  228), and nonobstructive (n  820). Overall
og-rank, p  0.001; myectomy versus nonoperated obstructive hypertro-h
h
hic cardiomyopathy, p  0.001; myectomy versus nonobstructive hyper-
rophic cardiomyopathy, p  0.8.ariate analysis including all three study groups (n  1,337)
onfirmed that myectomy had a strong, independent asso-
iation with both overall (p  0.001) and HCM-related
urvival (p  0.01).
When confining the analysis to those patients 45
ears old at study entry, thereby reducing the potentially
onfounding age-related co-morbidities such as coronary
rtery disease, patients treated with surgical myectomy
ontinued to show significantly better survival than non-
perated obstructive HCM patients (overall survival HR
.28; p  0.001; HCM-related survival HR 0.25; p 
.004). The 1-, 5-, and 10-year survival after myectomy
as 99%, 98%, and 92%, respectively, as compared with
2%, 88%, and 75%, respectively (log-rank p  0.006) for
he nonoperated obstructive HCM patients.
igure 4. Survival free from sudden cardiac death among patients in three
ypertrophic cardiomyopathy subgroups: surgical myectomy (n  289),
onoperated with obstruction (n  228), and nonobstructive (n  820).
verall log-rank, p  0.003; myectomy versus nonoperated obstructive
igure 3. Survival free from hypertrophic cardiomyopathy-related death
mong patients in three hypertrophic cardiomyopathy (HCM) subgroups:
urgical myectomy (n  289), nonoperated with obstruction (n  228),
nd nonobstructive (n  820). Overall log-rank, p  0.001; myectomy
ersus nonoperated obstructive hypertrophic cardiomyopathy, p  0.001;
yectomy versus nonobstructive hypertrophic cardiomyopathy, p  0.01.ypertrophic cardiomyopathy, p  0.003; myectomy versus nonobstructive
ypertrophic cardiomyopathy, p  0.3.
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ased on over four decades of worldwide experience, and
he recent American College of Cardiology-European
ociety of Cardiology Expert Consensus Guidelines,
eptal myectomy is considered the gold-standard strategy
or the relief of drug-refractory symptoms in HCM
atients with LV outflow obstruction (1–3,5–7). Septal
yectomy, by virtue of abolishing LV outflow obstruc-
ion and mitral regurgitation and normalizing intracar-
iac pressures, wall stress, myocardial oxygen demand,
etabolism, and coronary flow, has been shown consis-
ently to improve both exercise capacity and quality of life
12,15,24). Because of the cumulative experience and
mproved myocardial protection techniques, operative
ortality associated with myectomy has diminished dra-
atically from the initial surgical reports. At present,
rocedural risk is 1% to 2% at experienced centers, and,
n fact, has approached zero in the most recent patients
6,17,20,22,23,27,32–36).
Whether the salutary hemodynamic and clinical effects
f myectomy translate into enhanced long-term postop-
rative survival remains unresolved. Clarification of this
ivotal issue has been impeded by certain insurmountable
ractical and ethical obstacles implicit in performing
rospective, randomized trials comparing myectomy with
ther treatment strategies in severely symptomatic pa-
ients. These include the well-documented efficacy of
yectomy for relieving symptoms, the relative infre-
uency with which this operation is performed (i.e., 5%
f all HCM patients) (2,5,6), and the particularly long-
erm follow-up that would be required. It is unlikely that
uch trials will ever take place.
The present study provides the strongest evidence to date
howing that surgical relief of obstruction may improve
ong-term survival. Although this study is necessarily retro-
pective, we have taken the unique opportunity to assess
ong-term outcome after septal myectomy in one of the
ongest-standing and continuous surgical referral programs
7,14,24). Outcomes were compared with an age- and
ender-matched general U.S. population, and to recently
vailable cohorts of nonoperated HCM patients (4).
aken together, these data afford substantial evidence of
avorable (possibly enhanced) long-term survival after
urgical myectomy.
Long-term survival free from HCM-related mortality
fter myectomy was excellent (95% at 10 years). Further-
ore, the 10-year overall postoperative survival free from
ll-cause mortality did not differ from that of the general
opulation, suggesting that myectomy may afford pa-
ients the opportunity to achieve normal or near-normal
ongevity. This observation is of particular relevance
iven the youthful age (mean, 45 years) of the operated
atients. Notably, the comparison group of patients with
V outflow obstruction who did not undergo myectomy
xperienced a much less favorable outcome with greater phan twice the overall mortality risk observed in myec-
omy patients. These data also suggest that the likelihood
f sudden death was reduced after myectomy (compared
ith nonoperated patients); however, the events were not
bolished after operation, indicating that independent
isk stratification is still required for patients undergoing
his procedure (2,4,6,7).
Unavoidably, rigorous matching of myectomy and
onoperated patients was not possible. Nevertheless, we
egard the statistical comparisons and derived conclusions
alid and clinically relevant. First, the postoperative
urvival of myectomy patients was indistinguishable from
hat of the general population. Second, the multivariate
nalyses clearly identified myectomy as a strong, inde-
endent determinant of survival, substantiating that the
ifferences in long-term survival documented here are
ikely attributable to surgical relief of the subaortic
radient. Third, despite significantly more advanced
reoperative symptoms, myectomy patients nevertheless
howed long-term survival that greatly exceeded that of
he less symptomatic nonoperated obstructive HCM
atients. Fourth, analysis of patients 45 years old,
educing the potential for confounding age-related vari-
bles, showed nearly identical results to the primary
nalysis with a greater than three-fold increase in risk of
ortality among obstructive HCM patients managed
ithout surgery.
The operative results reported here represent those
chieved by an experienced surgical referral center and
herefore constitute a measure of the most favorable
utcome that can be expected from septal myectomy
6,7,16,24). Indeed, we believe that this surgical series
as most relevant to understanding the optimal benefits
hat can be achieved with surgical intervention in drug-
efractory, severely symptomatic patients with obstructive
CM. However, it is inappropriate to extrapolate these
ndings to low-volume surgical centers or alternative
reatment modalities such as catheter-based alcohol sep-
al ablation, for which follow-up is comparatively brief
nd post-procedural outcome is incompletely defined
6,35–37). In addition to showing an impressive survival
dvantage for myectomy, our data also support the
tandard recommendation to intervene in obstructive
CM patients (with myectomy, or selectively with alter-
atives such as alcohol septal ablation) when refractory
eart failure symptoms have progressed to NYHA func-
ional classes III to IV (6,7,24). However, we do not
egard as prudent using these data to justify or promote
arlier major interventions with more lenient eligibility
riteria in mildly symptomatic patients.
Survival analysis designs that include surgical patients
an be problematic in part because by definition surgical
atients have 100% survival up to the date of operation,
nd operative candidates who die while awaiting opera-
ion are not included in the analysis. The survival analysis
resented in this study was judged to be the most
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August 2, 2005:470–6 Survival After Myectomy for HCMppropriate and reliable model for these purposes. How-
ver, we had prospectively identified two additional
urvival analysis models. The first alternative model
xcluded all deaths in the nonoperated comparison HCM
roups that occurred within six months of study entry.
he second alternative strategy treated myectomy as a
ime-dependent variable with all operated and nonoper-
ted patients having the same study entry point, i.e., the
ate of first evaluation at each participating center. Most
mportantly, both of these alternative analyses yielded
ubstantially the same outcome results as the survival
odel used in the present study.
We prospectively defined cardiac events and the sta-
istical methodology based on precedent, and our judg-
ent that this strategy appropriately reflected the clinical
cenario studied here. Nonetheless, to examine whether
ur event definitions unduly influenced the results, we
etrospectively reanalyzed the data with implantable
ardioverter-defibrillator discharge and alcohol septal
blation considered as inconsequential (non-events) and
ardiac transplantation considered as a surrogate for
ardiac death. With these alternative definitions, the
urvival results were unchanged from the principal anal-
sis presented in the report.
In conclusion, the data presented here offer consider-
ble evidence showing that surgical myectomy in patients
ith obstructive HCM not only vastly improves quality
f life, but also enhances survival over that that would
therwise be expected as a consequence of longstanding
V outflow tract obstruction. In accord with contempo-
ary consensus panel recommendations (6), the present
ndings support septal myectomy as the primary treat-
ent for HCM patients with severe drug-refractory
ymptoms caused by LV outflow obstruction.
eprint requests and correspondence: Dr. Steve R. Ommen,
ayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
-mail: ommen.steve@mayo.edu.
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